ArticleOncoTargets and therapy2016
Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Case Report: Not all signet rings are of gastric origin: a case of lobular breast carcinoma metastatic to the stomach.Frontiers in oncology · 2026Article
- Epidemiology of early vs late recurrence among women with early stage estrogen receptor-positive breast cancer in the Pathways Study.Journal of the National Cancer Institute · 2024Article
- CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.Breast care (Basel, Switzerland) · 2023Article
- microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.Diagnostics (Basel, Switzerland) · 2020Article
- Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy.Hormones & cancer · 2020Article
- MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.Breast cancer research and treatment · 2020Article
- Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer.Therapeutic advances in medical oncology · 2020Article
- Incorporation of biologic factors for the staging of de novo stage IV breast cancer.NPJ breast cancer · 2020Article
- Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.Theranostics · 2018Article
- Prognostic role of progesterone receptor expression in a population-based analysis.Journal of cancer research and clinical oncology · 2017Article
- Cadherin-11 expression is upregulated in invasive human breast cancer.Oncology letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the prognostic value of progesterone receptor (PR) expression in patients with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer subgroups.
methodsA retrospective review of breast cancer patients who underwent mastectomy or breast-conserving surgery between January 1998 and December 2007 was performed. The prognostic impact of PR status on disease-free survival (DFS) was analyzed.
resultsOf the 1,301 patients included in this study, the median follow-up time was 64 months, and the median age was 46 years. There were 18.4% of patients (n=219) with PR negative (PR-) cancer. Women with PR-breast cancer were more likely to be postmenopausal (P<0.001) and have pN3 stage (P=0.031) and Stage III (P=0.049) cancer. Cox regression univariate and multivariate analysis showed that PR status was a significant prognostic factor for DFS. Patients with PR- status had poorer DFS (hazard ratio =1.626, 95% confidence interval =1.060-2.497, P=0.026). The 5-year DFS for patients with PR- and PR+ breast cancer was 79.4% and 86.2%, respectively, and the 8-year DFS for patients with PR- and PR+ breast cancer was 69.6% and 78.1%, respectively (P=0.012). A significant difference in DFS was observed between PR- and PR+ disease in patients with node-negative cancer, but was not for patients with lymph node metastasis (P=0.242). In premenopausal patients, DFS varied significantly by PR status (P=0.049). A marginally significant difference in DFS between the PR- and PR+ disease was seen in postmenopausal patients (log rank P=0.065).
conclusionLack of PR expression is associated with worse survival in patients with hormone receptor-positive and HER2-negative breast cancer subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.